This time TRMS actually got good sequential growth out of Fuzeon. The stock has recovered somewhat since I last posted on it, and it's up a few percent after hours. Folks might take this as a sign of recovery and run the stock some more; I'll probably just watch till next quarter. Though it might be worth checking the cash reserves. If they're a bit low, and they need to fund higher R&D as they move their next generation drug into later stage trials, they would likely take advantage of another rumble up to $15 or so, and kick out a fat offering . . .
>>Trimeris, Inc. (NASDAQ: TRMS - News) today announced worldwide net sales of FUZEON for the year were $208.2 million, up 54 percent from $135.2 million for 2004. Net sales of FUZEON in the U.S. and Canada for the year were $112.7 million, up 32 percent from $85.7 million for 2004. Net sales of FUZEON outside the U.S. and Canada for the year were $95.5 million, up 93 percent from $49.5 million for 2004. All sales of FUZEON are recorded by F. Hoffmann-La Roche Ltd., ("Roche"), Trimeris' collaborative partner.
On a quarterly basis, worldwide net sales of FUZEON were $62.9 million, up 58 percent from $39.8 million in the fourth quarter of 2004. Net sales of FUZEON in the U.S. and Canada were $35.8 million, up 48 percent from $24.2 million in the fourth quarter of 2004. Net sales of FUZEON outside the U.S. and Canada were $27.1 million, up 73 percent from $15.6 million in the fourth quarter of 2004.
"We are proud to have surpassed the $200 million mark for a product that is in its second full year from launch. These results were driven by several factors including, the growing acceptance of FUZEON as a core component of highly suppressive HIV therapy, synergy with new agents and the success of ongoing patient support programs. We are also very pleased to report that sales in North America were consistent with the guidance issued in early 2005," said Steven D. Skolsky, Chief Executive Officer of Trimeris.
2006 U.S and Canada FUZEON Sales Guidance
FUZEON sales in the U.S. and Canada are expected to range from $140 million to $150 million, up 24 to 33 percent from 2005.
A live webcast of our FUZEON sales conference call on January 31, 2006 at 4:15 p.m. Eastern Time will be available at trimeris.com.
The release of complete financial results will take place in early March 2006.<<
snip
Cheers, Tuck |
